ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression

Data show that diabetes-associated metabolic issues lead to kidney lipid accumulation, resulting in inflammation and fibrosis that cause progressive kidney damage and disease progression.Earlier data by Kanbay et al (Eur J Clin Invest. 2022) demonstrate that fatty kidney is an independent risk factor for chronic kidney disease (CKD), not just DKD, and reinforce that lipid accumulation promotes release of pro-inflammatory cytokines leading to inflammation, fibrosis, and CKD progression.ZyVersa is developing ...